.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC06_Dexlansoprazole.Dexlansoprazole .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC06_Dexlansoprazole.Dexlansoprazole| name: | Dexlansoprazole |
| ATC code: | A02BC06 | route: | oral |
| n-compartments | 1 |
Dexlansoprazole is a proton pump inhibitor (PPI) used for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders. It is the R-enantiomer of lansoprazole and is approved for use in many countries.
Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of dexlansoprazole delayed-release capsules.
Parekh, PJ, et al., & Johnson, DA (2014). Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). Expert opinion on pharmacotherapy 15(9) 1215–1222. DOI:10.1517/14656566.2014.911841 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24749891
Miura, M, et al., & Suzuki, T (2006). Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. International journal of clinical pharmacology and therapeutics 44(12) 605–613. DOI:10.5414/cpp44605 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17190370